Artivion, Inc. (AORT)

Market Cap	842.96M
Revenue (ttm)	354.00M
Net Income (ttm)	-30.69M
Shares Out	41.71M
EPS (ttm)	-0.75
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	196,971
Open	19.87
Previous Close	19.94
Day's Range	19.53 - 20.37
52-Week Range	12.16 - 21.90
Beta	1.67
Analysts	Strong Buy
Price Target	20.67 (+2.28%)
Earnings Date	May 2, 2024

About AORT

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shel...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 11, 1993
• Employees: 1,500
• Stock Exchange: NYSE
• Ticker Symbol: AORT

Financial Performance

In 2023, Artivion's revenue was $354.00 million, an increase of 12.82% compared to the previous year's $313.79 million. Losses were -$30.69 million, 59.9% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for AORT stock is "Strong Buy." The 12-month stock price forecast is $20.67, which is an increase of 2.28% from the latest price.

Price Target

$20.67

(2.28% upside)

Analyst Consensus: Strong Buy